ALHC · Alignment Healthcare, Inc.
$12.78
-0.45 (-3.40%)
At close · Aug 19
Market Cap
$2.74B
Shares
207.44M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$12.78
Open$13.15
Day$12.70–13.26
52W close$12.78–24.56
Avg vol 30d5.2M
Short int22.0M · 10.6% float · 4.6d
Short vol41%
Last earningsJul 30, 2026
DataMar 2021–Aug 2026
Filing10-Q · Jul 30
Up next
Next earnings call
Oct 30, 2026
Est · unconfirmed
· in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Jul 30, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Very Bullish
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−33%
below
Price vs 50-day avg
−33%
below
RSI (14)
30
oversold
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−38%
trailing
6-month return
−37%
trailing
YTD return
−35%
this year
Relative strength
−48%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $19 › 200d $19 — 200d above 50d
Institutional flow
Accumulating
+11% holders QoQ · +81 funds added
Insider flow
Accumulating
Net +$197.6K over 90 days · 0% sells
Short interest
Falling
10.63% of float · ▼ -11.1% MoM · 4.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
327 holders — near 3-yr high, broad support
Squeeze score
58
elevated · 0–100
Fundamentals
Revenue growth
+46%
Y/Y
EPS growth
+100%
Y/Y
Free cash flow
$113.1M
Balance sheet
$252.6M
net cash
Quant / Vol
risk profile
Volatility
62%
annualized · 1-yr
Max drawdown
−48%
past year
ATR
7.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Jul 30, 2026
Adjusted EBITDA
· Twelve Months Ending December 31, 2026
Non-GAAP
Initiated
$145M – $163M
Prior guidance
period ended
· from the Earnings Call filed Mar 31, 2026
Revenue
· second quarter
$1.3B – $1.32B
Adjusted EBITDA
· second quarter
$50M – $60M
Adjusted gross profit
· second quarter
$167M – $177M
Guided vs delivered
· last 4 settled
Revenue
first quarter
guided $590M – $600M
$628.6M
Beat +5.6%
Revenue
full year 2024
guided $2.38B – $2.41B
$2.7B
Beat +12.9%
Revenue
fourth quarter 2023
guided $422M – $442M
$465.39M
Beat +7.7%
Revenue
full-year 2023
guided $1.78B – $1.8B
$1.82B
Beat +1.9%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−33%
Bearish
Price vs 50-day avg
−33%
Bearish
RSI (14)
30
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 4 of 6
Trend (MA cross)
No cross
50d $19 › 200d $19 — 200d above 50d
Institutional flow
Accumulating
+11% holders QoQ · +81 funds added
Insider flow
Accumulating
Net +$197.6K over 90 days · 0% sells
Short interest
Falling
10.63% of float · ▼ -11.1% MoM · 4.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
327 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $13
Now $13 · 0%
Range high $25
vs 200-day avg -33%
vs 50-day avg -33%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $68.1M | Q2 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net income 36.56M
+0K Less: Net loss attributable to noncontrolling interest
+4.28M Interest expense
+7.86M Depreciation and amortization
+1.27M Income tax expense
+18.17M Equity-based compensation
+14K Litigation costs
-1K Gain on sale of property and equipment
= Adjusted EBITDA 68.15M
|
|||
| Adjusted gross profit non-GAAP | $182.9M | Q2 2026 | — |
GAAP → non-GAAP reconciliationGAAP Income from operations 42.1M
+1.89M Equity-based compensation (medical expenses)
+3K Depreciation (medical expenses)
+7.85M Depreciation and amortization
+131M Selling, general, and administrative expenses
= Adjusted Gross Profit 182.85M
|
|||
| Health plan membership | 294,100 | Q2 2026 | — |
|
|
|||
| Medical benefits ratio based on adjusted gross profit non-GAAP | 86.3% | Q2 2026 | — |
|
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Healthcare Plans — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ALHC
this stock
Alignment Healthcare, Inc.
|
$2.74B | -35.3% | +46.1% | — | 10.6% |
|
UNH
Unitedhealth Group Inc
|
$353.59B | +19.3% | +11.8% | — | 1.7% |
|
CVS
CVS HEALTH Corp
|
$119.95B | +18.0% | +7.8% | 24.8 | 1.5% |
|
ELV
Elevance Health, Inc.
|
$87.01B | +13.7% | +12.5% | 17.8 | 2.6% |
|
CI
Cigna Group
|
$74.37B | +0.8% | +11.2% | 11.7 | 1.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ALHC | -5.5% | -38.5% | -37.4% | -13.9% | -35.3% |
| SPY | -0.4% | +2.6% | +10.7% | +2.7% | +12.5% |
| vs SPY | -5.1% | -41.0% | -48.1% | -16.7% | -47.8% |
Key facts
CIK
1832466
CUSIP
01625V104
13F (30d)
301 filings
297 filers
Visit website
Investor relations